Novozymes (OTCPK:NVZM.F) - Stock Price, News & Analysis

NVZM.F Stock Overview

NVZM.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	3/6
Financial Health	4/6
Dividends	4/6

Rewards

Earnings are forecast to grow 17.49% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Has a high level of debt

Dividend of 1.64% is not well covered by cash flows

Novozymes A/S Competitors

PPG Industries

NYSE:PPG

US$31.4b

DuPont de Nemours

NYSE:DD

US$30.3b

Celanese

NYSE:CE

US$17.3b

RPM International

NYSE:RPM

US$13.9b

Price History & Performance

Summary of all time highs, changes and price drops for Novozymes
Historical stock prices
Current Share Price	kr.54.50
52 Week High	kr.62.80
52 Week Low	kr.38.85
Beta	0.48
1 Month Change	-6.44%
3 Month Change	7.52%
1 Year Change	2.04%
3 Year Change	-17.95%
5 Year Change	16.73%
Change since IPO	90.81%

Recent updates

Shareholder Returns

	NVZM.F	US Chemicals	US Market
7D	-0.1%	-3.1%	-3.7%
1Y	2.0%	5.4%	20.5%

Return vs Industry: NVZM.F underperformed the US Chemicals industry which returned 4.6% over the past year.

Return vs Market: NVZM.F underperformed the US Market which returned 20.2% over the past year.

Price Volatility

Is NVZM.F's price volatile compared to industry and market?
NVZM.F volatility
NVZM.F Average Weekly Movement	4.6%
Chemicals Industry Average Movement	5.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.0%

Stable Share Price: NVZM.F has not had significant price volatility in the past 3 months.

Volatility Over Time: NVZM.F's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1925	6,577	Ester Baiget	www.novozymes.com

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Novozymes A/S Fundamentals Summary

How do Novozymes's earnings and revenue compare to its market cap?
NVZM.F fundamental statistics
Market cap	US$25.51b
Earnings (TTM)	US$431.35m
Revenue (TTM)	US$2.55b

59.1x

P/E Ratio

10.0x

P/S Ratio

Is NVZM.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NVZM.F income statement (TTM)
Revenue	kr.17.90b
Cost of Revenue	kr.8.18b
Gross Profit	kr.9.72b
Other Expenses	kr.6.70b
Earnings	kr.3.02b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 28, 2024

Earnings per share (EPS)	6.51
Gross Margin	54.32%
Net Profit Margin	16.89%
Debt/Equity Ratio	51.6%

How did NVZM.F perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

88%

Payout Ratio

NVZM.F Stock Overview

Rewards

Risk Analysis

Novozymes A/S Competitors

NYSE:PPG

US$31.4b

NYSE:DD

US$30.3b

NYSE:CE

US$17.3b

NYSE:RPM

US$13.9b

Price History & Performance

Recent News & Updates

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Recent updates

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report First Half, 2023 Results on Aug 09, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Novozymes A/S Announces Executive Appointments, Effective April 2021

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

Novozymes A/S Announces Executive Changes

Novozymes A/S Announces Executive Changes

Firmenich and Novozymes Partner for Great-Tasting Yogurt with Unprecedented Sugar Reduction Performance

Novozymes A/S (CPSE:NZYM B) acquired Precisionbiotics Group Limited for €80 million.

Novozymes Omits to Provide Outlook for Second Half and Full Year of 2020

Shareholder Returns

Price Volatility

About the Company

Novozymes A/S Fundamentals Summary

59.1x

10.0x

Earnings & Revenue

Dividends

1.6%

88%